Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.

Last updated: March 24, 2025
Sponsor: Nizhny Novgorod Regional Clinical Oncology Center
Overall Status: Active - Recruiting

Phase

2

Condition

Cancer

Colon Cancer

Colon Cancer; Rectal Cancer

Treatment

Capecitabine

Oxaliplatin

Clinical Study ID

NCT06888843
CRR-2025
  • Ages 70-90
  • All Genders

Study Summary

All patients with locally advanced colorectal cancer after radical surgical intervention who have not previously received systemic antitumor treatment will be randomized into two groups receiving fluoropyrimidines in mono-regimen and in combination with oxaliplatin.

Main objectives:

  • to compare the 3-year disease-free survival and 5-year overall survival rates in the two groups.

  • to identify, through a comprehensive geriatric assessment among elderly patients, the groups that benefit most from adjuvant chemotherapy.

Patients will be treated until progression of the process is detected or the maximum effect of therapy is reached (the longest duration of treatment is 6 months).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 70 years and older;

  2. Obtaining informed consent to participate in the study;

  3. Morphologically confirmed diagnosis of colorectal cancer;

  4. Stage III colorectal cancer;

  5. Underwent radical surgical intervention for primary colorectal tumor;

  6. ECOG score of 0 - I;

  7. Life expectancy of more than 6 months;

  8. No history of systemic drug therapy for CRC;

  9. Adequate liver, kidney and bone marrow function;

  10. Absence of severe uncontrolled concomitant chronic diseases and acute illnesses.

Exclusion

Exclusion Criteria:

  1. Having previously received any systemic therapy for CRC;

  2. Time after surgical treatment of more than 12 weeks;

  3. Stage I-II and IV disease;

  4. Confirmed dihydropyrimidine dehydrogenase deficiency in blood by PCR (alteration ofalleles c.[190511G > A], c.[1679T >G],[2846A > T], [1129-5923C >G], [c.1236G>A(HapB3)]);

  5. Severe uncontrolled comorbid chronic diseases or acute illnesses;

  6. Presence of a second malignancy (except for previously cured malignancies);

  7. Any condition that, in the opinion of the physician, would interfere with the studyprocedures.

Study Design

Total Participants: 160
Treatment Group(s): 2
Primary Treatment: Capecitabine
Phase: 2
Study Start date:
February 01, 2025
Estimated Completion Date:
February 01, 2028

Study Description

The study is a single-center, open-label, randomized Phase II study. The study will be divided into a screening phase (4 weeks prior to inclusion in the study), a treatment phase (up to 6 months) and a long-term follow-up phase (up to 28 days from the end of treatment - follow-up to assess the safety of therapy, up to 3 years from the end of treatment to assess survival and follow-up).

During the screening phase, patients with MR CRC will undergo examinations to fulfill the inclusion and exclusion criteria for the study.

Next, elderly patients meeting these criteria-who have locally advanced colorectal cancer-will be randomized in a ratio of approximately 1:1 into 2 groups.

The study is planned to include 160 patients, 80 in each group, for a total of 160 patients.

Patient groups

  1. Capecitabine in mono-regimen

  2. PCT according to XELOX regimen Stratification factors - gender m/f, age <75 />75, presence of postoperative complications yes/no.

The patients will be treated until the progression is detected or the maximum effect of therapy is achieved (the longest duration of treatment is 8 cycles). At the end of the treatment period, all patients will enter the observation phase.

Connect with a study center

  • Research Institute of Clinical Oncology "Nizhny Novgorod Regional Clinical Oncological Dispensary"

    Nizhny Novgorod, 603126
    Russian Federation

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.